- Home
- KPRX vs INAB Comparison
KPRX vs INAB Comparison
Compare KPRX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- INAB
- Stock Information
- Founded
- KPRX 1998
- INAB 2016
- Country
- KPRX United States
- INAB United States
- Employees
- KPRX N/A
- INAB N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- INAB Health Care
- Exchange
- KPRX Nasdaq
- INAB Nasdaq
- Market Cap
- KPRX 9.2M
- INAB 9.1M
- IPO Year
- KPRX N/A
- INAB 2021
- Fundamental
- Price
- KPRX $2.65
- INAB $2.02
- Analyst Decision
- KPRX Strong Buy
- INAB Strong Buy
- Analyst Count
- KPRX 1
- INAB 2
- Target Price
- KPRX $10.00
- INAB $108.00
- AVG Volume (30 Days)
- KPRX 32.4K
- INAB 48.3K
- Earning Date
- KPRX 11-07-2025
- INAB 11-11-2025
- Dividend Yield
- KPRX N/A
- INAB N/A
- EPS Growth
- KPRX N/A
- INAB N/A
- EPS
- KPRX N/A
- INAB N/A
- Revenue
- KPRX N/A
- INAB N/A
- Revenue This Year
- KPRX N/A
- INAB N/A
- Revenue Next Year
- KPRX N/A
- INAB N/A
- P/E Ratio
- KPRX N/A
- INAB N/A
- Revenue Growth
- KPRX N/A
- INAB N/A
- 52 Week Low
- KPRX $2.25
- INAB $1.91
- 52 Week High
- KPRX $4.18
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- KPRX 46.53
- INAB 40.36
- Support Level
- KPRX $2.60
- INAB $1.91
- Resistance Level
- KPRX $2.80
- INAB $2.20
- Average True Range (ATR)
- KPRX 0.11
- INAB 0.11
- MACD
- KPRX -0.01
- INAB -0.01
- Stochastic Oscillator
- KPRX 21.21
- INAB 28.21
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.